Scolaris Content Display Scolaris Content Display

Cochrane Database of Systematic Reviews

精神分裂症患者的氯丙嗪剂量

Información

DOI:
https://doi.org/10.1002/14651858.CD007778.pub2Copiar DOI
Base de datos:
  1. Cochrane Database of Systematic Reviews
Versión publicada:
  1. 13 abril 2017see what's new
Tipo:
  1. Intervention
Etapa:
  1. Review
Grupo Editorial Cochrane:

  1. Grupo Cochrane de Esquizofrenia

Copyright:
  1. Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Cifras del artículo

Altmetric:

Citado por:

Citado 0 veces por enlace Crossref Cited-by

Contraer

Autores

  • Katharine Dudley

    Correspondencia a: Institute of Mental Health, University of Nottingham, Nottingham, UK

    [email protected]

  • Xiaomeng Liu

    Utrecht University, Utrecht, Netherlands

  • Saskia De Haan

    GGZ Noord Holland Noord, Alkmaar, Netherlands

Contributions of authors

Katharine Dudley ‐ data re‐extraction, 'Risk of bias' tables, 'Summary of findings' tables, analyses, re‐writing the report (2014, 2016 searches).
Saskia de Haan ‐ development of the protocol, data extraction, analyses, writing the report (2009 search).
Xiaomeng Liu ‐ development of the protocol, data extraction, analyses, writing the report (2009 search).

Sources of support

Internal sources

  • University of Nottingham, UK.

  • Utrecht University, Netherlands.

External sources

  • No sources of support supplied

Declarations of interest

None known.

Acknowledgements

We would like to thank the staff at the Cochrane Schizophrenia Group for their help and assistance, in particular Hirsto Girgorov for translating a Russian paper, Jun Xia for her help with Chinese papers and Farhad Shokraneh the Information Scientist. Special thanks to Professor Clive Adams for his guidance and support. We have used the generic text supplied by the Cochrane Schizophrenia Group for the Methods section and adapted it to our needs.

We would like to thank Lorna Lawrence for peer reviewing this review.

Version history

Published

Title

Stage

Authors

Version

2017 Apr 13

Chlorpromazine dose for people with schizophrenia

Review

Katharine Dudley, Xiaomeng Liu, Saskia De Haan

https://doi.org/10.1002/14651858.CD007778.pub2

2009 Apr 15

Chlorpromazine dose for people with schizophrenia

Review

Xiaomeng Liu, Saskia De Haan

https://doi.org/10.1002/14651858.CD007778

Differences between protocol and review

For the 2014 update, we included data from Wode‐Helgodt 1978 for extrapyramidal adverse effects that had been reported using a modification of a previously published scale (Simpson 1970). We realise that this is not entirely in keeping with our previous methods where we stated that we should not use any modified scales ‐ citing Marshall 2000. However, we felt these outcomes to be important although they must carry high risk of bias.

We have moved the outcome of leaving the study early to below global and mental state, moved 'death' to adverse effects.

PICO

Population
Intervention
Comparison
Outcome

El uso y la enseñanza del modelo PICO están muy extendidos en el ámbito de la atención sanitaria basada en la evidencia para formular preguntas y estrategias de búsqueda y para caracterizar estudios o metanálisis clínicos. PICO son las siglas en inglés de cuatro posibles componentes de una pregunta de investigación: paciente, población o problema; intervención; comparación; desenlace (outcome).

Para saber más sobre el uso del modelo PICO, puede consultar el Manual Cochrane.